Glatiramer acetate (Copaxone®) is an immunomodulatory polypeptide used in patients with relapsing–remitting multiple sclerosis. It represents a safe treatment option with mild side effects. In this study, we look at a 39-year-old woman who received glatiramer acetate as subcutaneous injections for two months and developed contact dermatitis. The drug had to be stopped, and treatment with topical prednisone was initiated. Prick/scratch testing was negative but the lymphocyte transformation test was highly positive for glatiramer acetate. This is the first report on contact dermatitis induced by glatiramer acetate injections. The treatment consisted of local topical steroids and cessation of the drug.
Fridikis-HareliMTeitelbaumDGurevichE. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cell specificity and promiscuity. Proc Natl Acad Sci USA1994; 91: 4872–4876.
2.
Fridkis-HareliMStromingerJL. Promiscuous binding of the synthetic copolymer 1 to purified HLA-DR molecules. J Immunol1998; 160: 4386–4397.
3.
RackeMKLovett-RackeAKarandikarNJ. The mechanism of action of glatiramer acetate treatment in multiple sclerosis. Neurology2010; 74: 25–30.
4.
DudaPKriegerJSchmiedMBalentineCHaflerD. Human and murine CD4 T cell reactivity to a complex antigen recognition of the synthetic random polypeptide glatiramer acetate. J Immunol2000; 165: 7300–7307.
5.
FarinaCBerghFTAlbrechtHMeindlEYassouridisANeuhausO. Treatment of multiple sclerosis with Copaxone (COP) Elispot assay detects COP-induced interleukin 4 and interferon γ response in blood cells. Brain2001; 124: 705–719.
6.
BrennerTArnonRSelaMAbramskyOMeinerZRiven-KreitmannR. Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone®. J Neuroimmunol2001; 115: 152–160.
7.
PichlerWJ. Delayed drug hypersensitivity reactions. Ann Intern Med2003; 139: 683–693.
8.
HofstadtULeclaireJRaguzJMHilkerOHanekeEJörgJ. Delayed-type hypersensitivity to glatiramer acetate (Copaxone): report of three cases (abstract). J Neurol1998; 418: 179.
9.
ZiemssenTNeuhausOHohlfeldR. Risk–benefit assessment of glatiramer acetate in multiple sclerosis. Drug Safety2001; 24: 979–990.
10.
FrohmannEMBrannonKAlexanderSSimsDPhillipsJTO’LearyS. Disease modifying agent related skin reactions in multiple sclerosis prevention, assessment and management. Mult Scler2004; 10: 302–307.
